<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919279</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190156</org_study_id>
    <nct_id>NCT03919279</nct_id>
  </id_info>
  <brief_title>Treatment of Erosive Digital Osteoarthritis by Transcutaneous Auricular Nerve Stimulation</brief_title>
  <acronym>ADEPT</acronym>
  <official_title>Transcutaneous Auricular Vagus Nerve Stimulation in Erosive Hand Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erosive hand osteoarthritis (EHOA) is a subtype of had osteoarthritis characterized by
      inflammation and pain, with subsequent burden. Few symptomatic treatments are available in
      EHOA, while this population with EHOA has frequently comorbidities.

      Stimulation of the vagus nerve (VN), belonging to parasympathetic system, dampens
      pro-inflammatory cytokines production by splenic macrophages, through to the binding of
      acetylcholine neurotransmitter to α7nicotinic receptor on macrophages: this is the
      cholinergic anti-inflammatory pathway (CAP). Beyond its anti-inflammatory effects, VNS is
      analgesic in chronic pain disorders (headache, fibromyalgia). Beside implantable devices, VNS
      may be performed using transcutaneous stimulation of the ascendant auricular branch of the VN
      (tVNS) at the left ear localized on the cymba conchae tVNS is well-tolerated therapy avoiding
      invasive neurosurgery.

      The investigator do the hypothesis that auricular tVNS using a transcutaneous electrical
      nerve stimulation (TENS) device could be a novel, simple and well-tolerated analgesic and
      anti-inflammatory treatment of symptomatic EHOA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In symptomatic and inflammatory EHOA patients, we will apply tNVNS using device from
      Schwa-Medico (TENSeco2 + auricular electrode + conductive gel) 25 Hz stimulation will be
      applied, intensity escalated up to 15 mA or below if tingling sensation.

      tVNS will be performed 1 hour daily for 1 month and we will assess EHOA symptoms (pain and
      function) at 1 month (end of the study)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Pain</measure>
    <time_frame>1 month</time_frame>
    <description>Self-reported hand pain in the previous 48h measured on a 100 mm visual analogic scale (VAS).
Scoring system:
0= No pain 5= Moderate pain 10= Worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>1 month</time_frame>
    <description>questionnaire Functional Index for Hand OsteoArthritis (FIHOA): scale minimum 0 , and maximum 30.
Scoring system of the FIHOA:
0 = possible without difficulty
= possible with slight difficulty
= possible with important difficulty
= impossible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect</measure>
    <time_frame>1 month</time_frame>
    <description>Safety : report of side effects during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time of daily use and cumulative time of use from the device's tracker</measure>
    <time_frame>1 month</time_frame>
    <description>Observance : Mean time of daily use and cumulative time of use during the 30 days before the 1 month visit collected from the device's tracker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of daily consumption of paracetamol</measure>
    <time_frame>1 month</time_frame>
    <description>Measure of Pain by daily consumption of paracetamol</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Erosive Osteo-Arthritis</condition>
  <condition>Hand Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>active arm with active tVNS for 1 month</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>active tVNS</intervention_name>
    <description>tVNS using TENS device from Schwa-Medico (TENSeco2) + auricular electrode applied on the left ear (Schwa-Medico) + conductive gel class I; 25 Hz stimulation 1 hour daily for 1 month</description>
    <arm_group_label>active arm with active tVNS for 1 month</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18 years

          -  Symptomatic HOA (1990 American College of Rheumatology criteria)

          -  EHOA according to hand radiographs with ≥1 erosive digital joints of proximal or
             distal interphalangeal joint (phases &quot;E&quot; or &quot;R&quot; of Verbruggen-Veys score)

          -  Visual Analogic Scale (VAS) for hand pain ≥ 40/100 at inclusion

             -≥1 interphalangeal joints symptomatic ≥ 3 months despite analgesics or non-steroidal
             anti-inflammatory drugs (NSAIDs) (or contraindicated)

          -  ≥1 symptomatic interphalangeal joint with clinical palpable synovitis at inclusion

          -  Informed written consent

        Exclusion Criteria:

          -  Isolated thumb-base OA (ie, rhizarthrosis)

          -  Hand osteoarthritis secondary to other known causes (eg gout, psoriatic arthritis)

          -  Psoriasis

          -  Current skin disease of the ear

          -  Ear canal not adapted to apply the auricular electrode

          -  History of severe cardiac disease (coronary artery disease, rhythm disturbance, heart
             failure, valvulopathy)

          -  Conduction or rhythm disturbances on electrocardiogram

          -  Symptomatic orthostatic hypotension or vasovagal syncope history

          -  History of vagotomy

          -  Pregnancy

          -  Fibromyalgia

          -  Use of other electrically active medical devices (eg pacemaker)

          -  Documented sleep apnea

          -  Use of corticosteroid (oral, intramuscular, intra-articular or intravenous),
             immunosuppressive agents, hyaluronic acid injection in interphalangeal joint within
             the last 3 months

          -  Hand surgery planned during the study period

          -  Pregnancy or breastfeeding if applicable

          -  Oral NSAIDs consumption during the last 48 hours before inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérémie Sellam, MD PhD PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology department Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erosive hand osteoarthritis</keyword>
  <keyword>pain</keyword>
  <keyword>inflammation</keyword>
  <keyword>vagus nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

